116 related articles for article (PubMed ID: 8445228)
1. An escalating dose regime of recombinant interferon-alpha 2A in the treatment of chronic hepatitis C.
Bosch O; Tapia L; Quiroga JA; Carreño V
J Hepatol; 1993 Feb; 17(2):146-9. PubMed ID: 8445228
[TBL] [Abstract][Full Text] [Related]
2. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
[TBL] [Abstract][Full Text] [Related]
3. Re-treatment of interferon-resistant patients with chronic hepatitis C with interferon-alpha.
Bresci G; Parisi G; Banti S; Capzia A
J Viral Hepat; 1995; 2(3):155-8. PubMed ID: 7493311
[TBL] [Abstract][Full Text] [Related]
4. Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
Ferenci P; Stauber R; Propst A; Fiedler R; Müller C; Gschwantler M; Schütze K; Datz C; Judmaier G; Vogel W; Krejs GJ; Gangl A
Dig Dis Sci; 1996 Dec; 41(12 Suppl):103S-108S. PubMed ID: 9011466
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients.
Yao G; Ji Y; Yang M; Xu D; Gao J; Wu X; Zhang Q; Hu D
Chin Med J (Engl); 1998 Oct; 111(10):922-6. PubMed ID: 11189241
[TBL] [Abstract][Full Text] [Related]
6. Recombinant interferon-alpha-2a for treatment of chronic hepatitis C: results of a multicenter randomized controlled dose study.
Imai Y; Kawata S; Tamura S; Ito N; Seki K; Nishiuchi M; Shinji Y; Kiriyama K; Himeno S; Minami Y; Kashihara T; Kawakami F; Maeda H; Yabuuchi I; Nishioka M; Shirai Y; Fukuda K; Kiso S; Ito T; Igura T; Doi Y; Matsuzawa Y
Liver; 1997 Apr; 17(2):88-92. PubMed ID: 9138278
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients.
Yao GB; Ji YY; Xu DZ; Gao J; Wu XH; Zhang QB; Hu DC
Hepatogastroenterology; 1999; 46(26):1059-64. PubMed ID: 10370667
[TBL] [Abstract][Full Text] [Related]
8. Human leucocyte interferon-alpha in chronic hepatitis C resistant to recombinant or lymphoblastoid interferon-alpha: a randomized controlled trial.
Gaeta GB; Di Virgilio D; Russo G; Stornaiuolo G; Nicolella U; Colella F; Grimaldi M; Pasquale G; Giusti G
J Viral Hepat; 1997 May; 4(3):209-14. PubMed ID: 9181530
[TBL] [Abstract][Full Text] [Related]
9. Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV-positive patients.
Marriott E; Navas S; del Romero J; García S; Castillo I; Quiroga JA; Carreño V
J Med Virol; 1993 Jun; 40(2):107-11. PubMed ID: 8395552
[TBL] [Abstract][Full Text] [Related]
10. Long-term titrated recombinant interferon-alpha 2a in chronic hepatitis C: a randomized controlled trial.
Rumi MG; del Ninno E; Parravicini ML; Romeo R; Soffredini R; Donato MF; Zahm F; Colombo M
J Viral Hepat; 1995; 2(2):73-6. PubMed ID: 7493300
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic hepatitis C by continuous subcutaneous infusion of interferon-alpha.
Carreño V; Tapia L; Ryff JC; Quiroga JA; Castillo I
J Med Virol; 1992 Jul; 37(3):215-9. PubMed ID: 1331310
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony-stimulating factor plus recombinant interferon-alpha.
Pardo M; Castillo I; Navas S; Carreño V
J Med Virol; 1995 Apr; 45(4):439-44. PubMed ID: 7545214
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis.
Senturk H; Uzunalimoglu O; Batur Y; Simsek I; Mert A; Ozbay G; Cetinkaya H; Ersoz G; Tabak F; Akbaylar H; Akdogan M; Dokmeci A; Sonsuz A; Ozenirler S; Erden E; Tozum N
Dig Dis Sci; 1997 Jul; 42(7):1438-44. PubMed ID: 9246043
[TBL] [Abstract][Full Text] [Related]
14. The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results.
Kullavanuaya P; Treeprasertsuk S; Thong-Ngam D; Chaermthai K; Gonlachanvit S; Suwanagool P
J Med Assoc Thai; 2001 Jun; 84 Suppl 1():S462-8. PubMed ID: 11529376
[TBL] [Abstract][Full Text] [Related]
15. Two years versus six months of interferon therapy for chronic hepatitis C.
Farrell GC
Dig Dis Sci; 1996 Dec; 41(12 Suppl):93S-98S. PubMed ID: 9011483
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and side effects of intermittent recombinant interferon-alpha 2a in chronic aggressive hepatitis C: with or without initial daily administration.
Itoh H; Nakata H; Yokoya Y; Nakashima S; Yamanishi T; Hara T; Kawai J; Miyamoto H; Higashi K; Nishioka S
J Gastroenterol Hepatol; 1996 Aug; 11(8):718-23. PubMed ID: 8872767
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM.
Douglas DD; Rakela J; Lin HJ; Hollinger FB; Taswell HF; Czaja AJ; Gross JB; Anderson ML; Parent K; Fleming CR
Dig Dis Sci; 1993 Apr; 38(4):601-7. PubMed ID: 8384978
[TBL] [Abstract][Full Text] [Related]
19. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks.
Reichard O; Foberg U; Frydén A; Mattsson L; Norkrans G; Sönnerborg A; Wejstål R; Yun ZB; Weiland O
Hepatology; 1994 Feb; 19(2):280-5. PubMed ID: 7507462
[TBL] [Abstract][Full Text] [Related]
20. Fixed versus titrated interferon-alpha 2B in chronic hepatitis C. A randomized controlled multicenter trial. The Swiss Association for the Study of the Liver.
Reichen J; Bianchi L; Bühler H; Dolivo N; Gonvers JJ; Lavanchy D; Malé PJ; Renner EL; Solioz M; Schmid M; Zimmermann A
J Hepatol; 1996 Sep; 25(3):275-82. PubMed ID: 8895005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
